As shown in Figure 3, the percentages of circulating GLK-expressing T-cells and the relative expression levels (fold) of GLK proteins as well as transcripts were significantly decreased (mean ± standard error of the mean, 45.77 ±5.58% versus 20.11 ±2.53%; 3.01 ±0.49 versus 0.93 ±0.17; and 3.45 ±0.56 versus 1.21 ±0.38, respectively, all P <0.005), paralleling clinical remission and the decrease in serum levels of sIL-2R (747.8 ±131.8 pg/mL versus 229.1 ± 38.5 pg/mL, P <0.005) in patients with AOSD after effective therapy. This evidence concerns the gene MAP4K3 and adult-onset Still disease.